Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHAYLA M BERGMANN

Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology

NPI
1730143645
CMS profile
214770
Location
BEAUFORT, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$28,307.86

31 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Inc $18,520.37 19
Genentech USA, Inc. $6,012.49 8
Chiesi USA, Inc. $2,100.00 1
Takeda Pharmaceuticals U.S.A., Inc. $1,150.00 1
GENZYME CORPORATION $375.00 1
Alexion Pharmaceuticals, Inc. $150.00 1

Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHAYLA M BERGMANN

NPI 1730143645 · CMS profile ID 214770

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Hematology-Oncology

BEAUFORT, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730143645?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHAYLA M BERGMANN, NPI 1730143645, CMS profile ID 214770. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730143645?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SHAYLA M BERGMANN, NPI 1730143645, CMS profile ID 214770. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730143645?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SHAYLA M BERGMANN, NPI 1730143645, CMS profile ID 214770, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1730143645?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

31 matching records · $28,307.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 31 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–31 of 31.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $375.0012/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843767709 CMS
Novo Nordisk Inc $1,700.0011/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811595791 CMS
Genentech USA, Inc. $436.7911/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835977009 CMS
Genentech USA, Inc. $4,675.0011/11/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835976999 CMS
Genentech USA, Inc. $306.4411/11/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835977003 CMS
Genentech USA, Inc. $138.4611/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835977005 CMS
Genentech USA, Inc. $203.2411/11/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835977011 CMS
Genentech USA, Inc. $17.0311/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835977015 CMS
Genentech USA, Inc. $35.0011/11/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835977017 CMS
Genentech USA, Inc. $200.5311/11/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835977021 CMS
Novo Nordisk Inc $88.4809/21/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810645141 CMS
Novo Nordisk Inc $110.0509/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811515073 CMS
Novo Nordisk Inc $245.2809/21/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811752471 CMS
Novo Nordisk Inc $360.3509/21/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811752475 CMS
Novo Nordisk Inc $367.4109/21/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811752477 CMS
Novo Nordisk Inc $3,655.0009/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811752481 CMS
Alexion Pharmaceuticals, Inc. $150.0008/29/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783141757 CMS
Novo Nordisk Inc $3,485.0008/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810645137 CMS
Novo Nordisk Inc $60.4808/11/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811303084 CMS
Novo Nordisk Inc $144.8108/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811303089 CMS
Novo Nordisk Inc $183.6808/11/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811303093 CMS
Novo Nordisk Inc $708.4808/11/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811303099 CMS
Novo Nordisk Inc $321.4008/11/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811303159 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,150.0008/02/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 860924513 CMS
Novo Nordisk Inc $111.4506/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811303079 CMS
Novo Nordisk Inc $3,315.0006/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811459079 CMS
Novo Nordisk Inc $1,360.0004/30/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811698293 CMS
Novo Nordisk Inc $170.0004/09/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811143597 CMS
Novo Nordisk Inc $433.5003/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810772551 CMS
Novo Nordisk Inc $1,700.0002/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810948985 CMS
Chiesi USA, Inc. $2,100.0001/21/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849042797 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $33,400.59 36
PY2020 $17,392.19 22
PY2021 $28,307.86 31
PY2022 $56,578.29 50
PY2023 $25,272.75 24
PY2024 $93,551.59 58
PY2025 $32,786.96 24

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $182,096.67 57
PY2024 Recipient $330.00 1
PY2024 Principal investigator $123,216.25 29
PY2023 Recipient $7,690.97 4
PY2023 Principal investigator $204,898.80 60
PY2022 Recipient $2,500.00 1
PY2022 Principal investigator $196,214.82 57
PY2021 Principal investigator $297,011.90 78
PY2020 Principal investigator $507,163.73 79
PY2019 Recipient $14,782.04 33
PY2019 Principal investigator $370,237.09 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

57 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $294.00 12/19/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267940
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $104.00 12/19/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267942
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $94.00 12/19/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267944
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $87.00 12/19/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267946
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $242.00 12/19/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267948
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,236.00 12/19/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267950
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,551.00 11/20/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267924
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,259.00 11/20/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267926
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $87.00 11/20/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267928
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,756.00 11/20/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267930
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,300.00 11/12/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267916
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $715.00 11/12/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267918
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 11/12/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267920
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,217.00 11/12/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267922
Principal investigator 1 Novo Nordisk AS $581.49 10/14/2025 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
4202-HEM-301 No dispute reported 06/30/2026 1214104611
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,972.00 09/05/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267902
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $472.00 09/05/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267904
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $300.00 09/05/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267906
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $260.00 09/05/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267908
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $172.00 09/05/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267910
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $72.00 09/05/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267912
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $15,951.00 08/01/2025 Non-covered Recipient Entity
Medical University of South Carolina
AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXELOTOR No dispute reported 06/30/2026 1228742395
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,262.00 08/01/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267868
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,560.00 08/01/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267870
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,170.00 08/01/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267872
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,337.80 07/09/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267860
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,204.00 07/09/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267862
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $452.00 07/09/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267864
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,972.00 05/23/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267856
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,045.00 05/23/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267858
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 04/22/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267842
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $757.00 04/22/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267844
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $601.00 04/22/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267846
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,450.00 04/22/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267848
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 04/22/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267850
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,365.00 04/22/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267852
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,217.00 04/22/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1223267854
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15,500.00 04/15/2025 Non-covered Recipient Entity
Medical University Of South Carolina
US observational study of DE oral pellets in patients <12 y No dispute reported 06/30/2026 1220810472
Principal investigator 1 PFIZER INC. $350.00 03/10/2025 Non-covered Recipient Entity
Medical University of South Carolina
AN OPENLABEL EXPANDED ACCESS PROTOCOL FOR PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE WHO HAVE NO ALTERNATIVE TREATMENT OPTIONS No dispute reported 06/30/2026 1228727917
Principal investigator 1 PFIZER INC. $5,390.01 03/03/2025 Non-covered Recipient Entity
Medical University of South Carolina
AN OPENLABEL EXPANDED ACCESS PROTOCOL FOR PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE WHO HAVE NO ALTERNATIVE TREATMENT OPTIONS No dispute reported 06/30/2026 1228725574
Principal investigator 1 PFIZER INC. $528.97 03/03/2025 Non-covered Recipient Entity
Medical University of South Carolina
AN OPENLABEL EXPANDED ACCESS PROTOCOL FOR PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE WHO HAVE NO ALTERNATIVE TREATMENT OPTIONS No dispute reported 06/30/2026 1228727919
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 03/03/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267824
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $845.00 03/03/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267826
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 03/03/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267828
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,950.00 03/03/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267830
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,402.00 03/03/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267832
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,525.00 03/03/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267834
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,575.00 03/03/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
TAK-577-3001 A Phase 3, prospective, open-label, uncontrolled, multicenter study on efficacy and safety of prophylaxis with rVWF in children diagnosed with severe von Willebrand disease (VWD) No dispute reported 06/30/2026 1223267836
Principal investigator 1 PFIZER INC. $4,950.00 02/20/2025 Non-covered Recipient Entity
Medical University Of South Carolina
A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT No dispute reported 06/30/2026 1228767182
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $17,023.50 02/19/2025 Non-covered Recipient Entity
Medical University of South Carolina
AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXELOTOR No dispute reported 06/30/2026 1228764269
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $25,000.00 02/19/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 1223267806
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,720.00 02/19/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 1223267808
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,000.00 02/19/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 1223267810
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,300.00 02/19/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 1223267812
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,300.00 02/19/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 1223267814
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $435.00 02/19/2025 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 1223267816
Principal investigator 1 PFIZER INC. $1,186.90 02/02/2025 Non-covered Recipient Entity
Medical University of South Carolina
AN OPENLABEL EXPANDED ACCESS PROTOCOL FOR PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE WHO HAVE NO ALTERNATIVE TREATMENT OPTIONS No dispute reported 06/30/2026 1228726784